OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Other Events

OpGen, Inc. (NASDAQ:OPGN) Files An 8-K Other Events
Item 8.01 Other Events.

On June 3, 2020, OpGen, Inc. issued a press release announcing an update on its partnership with the New York State Department of Health. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Document
99.1 Press Release issued by OpGen, Inc. dated June 3, 2020
 
 
 


OPGEN INC Exhibit
EX-99.1 2 ex99x1.htm EXHIBIT 99.1 Exhibit 99.1         OpGen Expands Partnership with New York State Department of Health and IDC to Detect Antimicrobial-Resistant Infections   ·Collaboration with NYS Department of Health’s Wadsworth Center continues for second year term ·Project to utilize OpGen’s Acuitas® AMR Gene Panel and Acuitas Lighthouse® Software within digital health and precision medicine platform at multiple healthcare institutions   GAITHERSBURG,…
To view the full exhibit click here

Story continues below

About OpGen, Inc. (NASDAQ:OPGN)

OpGen, Inc. (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms. Its deoxyribonucleic acid (DNA) tests and bioinformatics address the threat of anti-biotic resistance by helping physicians and healthcare providers manage patient care decisions and protect the hospital biome through customized screening and surveillance solutions. It is working to deliver its molecular information solution to a global network of customers and partners. It is also working to provide precise diagnostic information powered by pathogen surveillance data. The Company’s high-resolution DNA tests are marketed under the Acuitas trade name.

An ad to help with our costs